Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia. (4th March 2021)

• Record Type: Journal Article
• Authors: Ferrari, Filipe; Martins, Vítor M.; Rocha, Viviane Z.; Santos, Raul D.
• Is Part Of: Expert opinion on pharmacotherapy. Volume 22:Number 4(2021)
• Page Start: 483
• Page End: 495
• Publication Date: 2021-03-04
• Subjects: Statins -- familial hypercholesterolemia -- atherosclerosis -- pediatric -- coronary heart disease -- cholesterol; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2020.1832991
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Familial hypercholesterolemia (FH) is a frequent genetic disorder characterized by elevated LDL-cholesterol (LDL-C) and early onset of atherosclerosis. Areas covered: The authors provide an overview of the pediatric FH scenario, with emphasis on the role of statins as the preferred pharmacological therapy, discussing their potential benefits, as well as adverse effects, and the remaining uncertainties about their use in this population. They also comment on other lipid-lowering therapies. Expert opinion: Statin therapy is recommended after the ages of 8–10 years old for heterozygous FH patients and can reduce LDL-C by 24–50% depending on drug type and dosage. For more severe cases, higher doses and adjuvant therapies like ezetimibe may be necessary and treatment should be started at diagnosis, as is the case of homozygous FH. Statins reduce progression of subclinical vascular disease and may reduce early cardiovascular events. The available evidence indicates safety of statins in children with no apparent harms related to growth, sexual maturation, steroid hormones, glucose levels, cognitive function, or muscle and liver problems, in comparison with placebo. Newer treatments like lomitapide, PCSK9 inhibitors, bempedoic acid and evinacumab need to be adequately evaluated in pediatric FH patients with more severe dyslipidemia.